

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 72746

**Title:** A modified EASL-CLIF criteria that is easier to use and perform better to prognosticate ACLF

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 00199582

**Position:** Editorial Board

**Academic degree:** MD, MSc, PhD

**Professional title:** Adjunct Professor, Attending Doctor, Doctor

**Reviewer's Country/Territory:** Brazil

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-10-26

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-10-27 10:32

**Reviewer performed review:** 2021-10-27 13:17

**Review time:** 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input checked="" type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

## SPECIFIC COMMENTS TO AUTHORS

The subject of improving the diagnostic criteria for ACLF is of great importance, especially considering the need of a universal definition for this condition. Nevertheless, some considerations on this study are in order. Minor comments: -Please avoid abbreviations in the title. The title should not begin with "A" as per journal style. -Please avoid long expressions as key words. -The Abstract must have at least 350 words as per journal style. Please also see the length recommended for each section. It is not clear in the Abstract why the authors consider mEACLF easier to use than EASL-ACLF (in the Abstract, there only seems to be a change in cutoff points). Nevertheless, even after understanding the simplification suggested for ACLF grade 1, it does not seem to make much of a difference in terms of easiness to use. -In Introduction, page 3, lines 3-4, ACLF is spelled out incorrectly. In the same page, APASL also is spelled out incorrectly (Asian x Asia) and there is a parenthesis symbol missing. -In Results, page 7, lines 21-22, the sentence is not clear and should be rephrased. -The references list should meet journal style. -In Table 1, "T" is standing for "circulatory failure". Authors should amend this. Major comments: -The definition of ACLF implies the presence of acute decompensation of cirrhosis, associated with organ failures and high short-term mortality. A database of outpatients is probably not appropriate for denifying a condition requiring the presence of acute decompensation of cirrhosis. Considering that most of their patients probably were not hospitalized, authors should discuss this limitation of their study. This might even explain why 30-day mortality rates for EASL-ACLF were lower than in other studies. -Since the concept of ACLF implies a high short-term mortality, authors should justify the diagnosis of ACLF by mEACLF criteria in patients with a 30-day mortality <15%



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

(for mEACLF grade 1, the mortality was only 4.7%). -If authors are suggesting that any single organ failure would lead to the diagnosis of ACLF, they should inform the mortality rate of ACLF grade 1 patients according to the different organ failures. -Authors must acknowledge the limitations of working with a large administrative database, which was not developed with the purpose of this study and which lacks the granularity for obtaining important information. The lack of data on PaO<sub>2</sub>/FiO<sub>2</sub> (or SpO<sub>2</sub>/FiO<sub>2</sub>) probably impaired the performance of the EASL-ACLF criteria. -Moreover, using such a large database comes with certain drawbacks, as the fact that clinically irrelevant differences might reach statistical significance. Authors should explain if they believe there is a clinically relevant difference in the prognostic performances of both criteria (for instance, 0.842 × 0.835 or 0.859 × 0.851, including an intersection of confidence intervals). -Furthermore, it is expected that cutoff points derived from a given population would perform better in that population than cutoff points derived from different populations. Therefore, the results of this study must be validated in other populations before mEACLF could be considered better than EASL-ACLF.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 72746

**Title:** A modified EASL-CLIF criteria that is easier to use and perform better to prognosticate ACLF

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03668558

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Consultant Physician-Scientist, Doctor

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-10-26

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-11-11 05:32

**Reviewer performed review:** 2021-11-12 05:52

**Review time:** 1 Day

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	---

## SPECIFIC COMMENTS TO AUTHORS

I would like to thank for the opportunity to revise this manuscript. This was a paper which proposed a modified classification for ACLF, based on EASL-CLIF Criteria. The Authors retrospectively evaluated a large number of patients who were listed for transplantation in the UNOS database. The Authors modified INR and serum creatinine levels from the original EASL-CLIF criteria. Therefore, a non irrelevant number of patients, previously without diagnosis of ACLF according to original criteria, now fulfilled criteria of ACLF. The second improvement of this study was the creation of a smooth definition of ACLF grades (deleting previously definition of ACLF grade 1b). The paper is of interest, in my opinion. Statistical analysis is good, as well as references. The Authors adequately discussed their findings in the appropriate section. No typos are present. I have only two comments. - First, mechanical ventilation should not be considered a surrogate of respiratory failure in all patients with ACLF (for instance, a patient with hepatic encephalopathy grade IV must be intubated without respiratory failure). This point should be discussed in the appropriate section. - Second, the use of "presence of vasopressors" (Table 1) without including MAP is another important difference from previous EASL-CLIF criteria. This point should be better discussed.